Acute exposure to doxorubicin results in increased cardiac P-glycoprotein expression

Journal of Pharmaceutical Sciences

Volumn 100, Issue 9, 2011, Pages 3951-3958

  Budde, Thomas ^a   Haney, Jeanette ^a,c   Bien, Sandra ^a   Schwebe, Matthias ^a   Riad, Alexander ^b   Tschöpe, Carsten ^b   Staudt, Alexander ^a,d   Jedlitschky, Gabriele ^a   Felix, Stephan B ^a   Kroemer, Heyo K ^a   Grube, Markus ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c Department of Medical Science and Operations   (Germany)

^d HELIOS KLINIKEN SCHWERIN   (Germany)

Author keywords

Cardiomyopathy; Cardiotoxicity; Doxorubicin; Drug transport; Efflux pumps; Heart; P glycoprotein; Pharmacokinetics; Toxicity

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER B1A; ABC TRANSPORTER B1B; DAUNORUBICIN; DOXO CELL; DOXORUBICIN; GLYCOPROTEIN P; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARDIOTOXICITY; CELL VIABILITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EXPOSURE; GENE EXPRESSION REGULATION; HEART LEFT VENTRICLE; HEART MUSCLE CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; UPREGULATION; WESTERN BLOTTING;

EID: 79960124668     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22622     Document Type: Article

References (40)

1. Zuppinger C, Timolati F, Suter TM. 2007. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol 7:61-66.
2. Singal PK, Iliskovic N, Li T, Kumar D. 1997. Adriamycin cardiomyopathy: Pathophysiology and prevention. FASEB J 11:931-936.
3. Doroshow JH. 1983. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43:460-472.
4. Singal PK, Deally CM, Weinberg LE. 1987. Subcellular effects of adriamycin in the heart: A concise review. J Mol Cell Cardiol 19:817-828.
5. Wallace KB. 2007. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 7:101-107.
6. Takemura G, Fujiwara H. 2007. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49:330-352.
7. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ. 1982. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133-139.
8. Cusack BJ, Young SP, Driskell J, Olson RD. 1993. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 32:53-58.
9. Ueda K, Cardarelli C, Gottesman MM, Pastan I. 1987. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 84:3004-3008.
10. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG. 1994. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357-361.
11. Bakos E, Homolya L. 2007. Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch 453:621-641.
12. Huls M, Russel FG, Masereeuw R. 2009. The role of ATP binding cassette transporters in tissue defense and organ regeneration. J Pharmacol Exp Ther 328:3-9.
13. Flens MJ, Zaman GJ, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, de Haas M, Meijer CJ, Scheper RJ. 1996. Tissue distribution of the multidrug resistance protein. Am J Pathol 148:1237-1247.
14. Meissner K, Sperker B, Karsten C, Zu Schwabedissen HM, Seeland U, Bohm M, Bien S, Dazert P, Kunert-Keil C, Vogelgesang S, Warzok R, Siegmund W, Cascorbi I, Wendt M, Kroemer HK. 2002. Expression and localization of P-glycoprotein in human heart: Effects of cardiomyopathy. J Histochem Cytochem 50:1351-1356.
15. Cayre A, Moins N, Finat-Duclos F, Maublant J, Albuisson E, Verrelle P. 1996. In vitro detection of the MDR phenotype in rat myocardium: Use of PCR, [3H]daunomycin and MDR reversing agents. Anticancer Drugs 7:833-837.
16. Estevez MD, Wolf A, Schramm U. 2000. Effect of PSC 833, verapamil and amiodarone on adriamycin toxicity in cultured rat cardiomyocytes. Toxicol In Vitro 14:17-23.
17. Solbach TF, Paulus B, Weyand M, Eschenhagen T, Zolk O, Fromm MF. 2008. ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch Pharmacol 377:231-243.
18. Jungsuwadee P, Nithipongvanitch R, Chen Y, Oberley TD, Butterfield DA, St Clair DK, Vore M. 2009. Mrp1 localization and function in cardiac mitochondria after doxorubicin. Mol Pharmacol 75:1117-1126.
19. Sridhar R, Dwivedi C, Anderson J, Baker PB, Sharma HM, Desai P, Engineer FN. 1992. Effects of verapamil on the acute toxicity of doxorubicin in vivo. J Natl Cancer Inst 84:1653-1660.
20. Zhang Y, Berger SA. 2003. Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo. Cancer Chemother Pharmacol 51:407-414.
21. van Asperen J, van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH. 1999. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer 79:108-113.
22. Bien S, Riad A, Ritter CA, Gratz M, Olshausen F, Westermann D, Grube M, Krieg T, Ciecholewski S, Felix SB, Staudt A, Schultheiss HP, Ewert R, Volker U, Tschope C, Kroemer HK. 2007. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res 67:10428-10435.
23. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, Izzo NJ Jr. 1998. HL-1 cells: A cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A 95:2979-2984.
24. Kubin T, Ando H, Scholz D, Bramlage P, Kostin S, van Veen A, Heling A, Hein S, Fischer S, Breier A, Schaper J, Schaper W. 1999. Microvascular endothelial cells remodel cultured adult cardiomyocytes and increase their survival. Am J Physiol 276:H2179-H2187.
25. Piper HM, Probst I, Schwartz P, Hutter FJ, Spieckermann PG. 1982. Culturing of calcium stable adult cardiac myocytes. J Mol Cell Cardiol 14:397-412.
26. Springer JE, Azbill RD, Carlson SL. 1998. A rapid and sensitive assay for measuring mitochondrial metabolic activity in isolated neural tissue. Brain Res Brain Res Protoc. 2:259-263.
27. Shan K, Lincoff AM, Young JB. 1996. Anthracycline-induced cardiotoxicity. Ann Intern Med 125:47-58.
28. Menna P, Recalcati S, Cairo G, Minotti G. 2007. An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovasc Toxicol 7:80-85.
29. Okabe M, Szakacs G, Reimers MA, Suzuki T, Hall MD, Abe T, Weinstein JN, Gottesman MM. 2008. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 7:3081-3091.
30. Okabe M, Unno M, Harigae H, Kaku M, Okitsu Y, Sasaki T, Mizoi T, Shiiba K, Takanaga H, Terasaki T, Matsuno S, Sasaki I, Ito S, Abe T. 2005. Characterization of the organic cation transporter SLC22A16: A doxorubicin importer. Biochem Biophys Res Commun 333:754-762.
31. Ho RH, Kim RB. 2005. Transporters and drug therapy: Implications for drug disposition and disease. Clin Pharmacol Ther 78:260-277.
32. Oswald S, Grube M, Siegmund W, Kroemer HK. 2007. Transporter-mediated uptake into cellular compartments. Xenobiotica 37:1171-1195.
33. Jungsuwadee P, Cole MP, Sultana R, Joshi G, Tangpong J, Butterfield DA, St Clair DK, Vore M. 2006. Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice. Mol Cancer Ther 5:2851-2860.
34. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, Vonhof S, Bickeboller H, Toliat MR, Suk EK, Tzvetkov M, Kruger A, Seifert S, Kloess M, Hahn H, Loeffler M, Nurnberg P, Pfreundschuh M, Trumper L, Brockmoller J, Hasenfuss G. 2005. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112:3754-3762.
35. Hu XF, Slater A, Wall DM, Kantharidis P, Parkin JD, Cowman A, Zalcberg JR. 1995. Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Br J Cancer 71:931-936.
36. Maitra R, Halpin PA, Karlson KH, Page RL, Paik DY, Leavitt MO, Moyer BD, Stanton BA, Hamilton JW. 2001. Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression. Biochem J 355:617-624.
37. Kohno K, Sato S, Takano H, Matsuo K, Kuwano M. 1989. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commun 165:1415-1421.
38. Hui RC, Francis RE, Guest SK, Costa JR, Gomes AR, Myatt SS, Brosens JJ, Lam EW. 2008. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther 7:670-678.
39. Guo J, Gertsberg Z, Ozgen N, Steinberg SF. 2009. p66Shc links alpha1-adrenergic receptors to a reactive oxygen species-dependent AKT-FOXO3A phosphorylation pathway in cardiomyocytes. Circ Res 104:660-669.
40. Volkova M, Palmeri M, Russell KS, Russell RR. 2011. Activation of the aryl hydrocarbon receptor by doxorubicin mediates cytoprotective effects in the heart. Cardiovasc Res 90:305-314.